POTASSIUM CHLORIDE IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE IN PLASTIC CONTAINER (POTASSIUM CHLORIDE IN PLASTIC CONTAINER).

How it works

Potassium chloride dissociates to potassium ions, which are essential for maintenance of intracellular tonicity, nerve impulse conduction, muscle contraction, and cardiac function.

What the body does with it

Metabolism	Potassium is not metabolized but is primarily excreted by the kidneys. Excreted mainly as potassium ions in urine.
Excretion	Primarily renal (90% excreted unchanged in urine); minor fecal elimination (<10%) via unabsorbed potassium.
Half-life	No classical terminal half-life; plasma potassium is rapidly regulated by cellular uptake and renal excretion, with equilibration half-life of ~1-2 hours in normal renal function.
Protein binding	Not protein-bound (free ion; negligible binding to albumin).
Volume of Distribution	0.5-0.6 L/kg (total body water); distributes primarily in extracellular fluid (14% of body weight).
Bioavailability	Oral: 90-100% (well absorbed from small intestine); IV: 100%.
Onset of Action	IV: Immediate (within seconds to minutes); oral: 30-60 minutes.
Duration of Action	IV: 2-4 hours (rapid redistribution and excretion); oral: 4-6 hours (sustained-release formulations up to 8-12 hours).

Classification & Brands

Dosing & administration

10-20 mEq intravenously over 1 hour, not exceeding 10 mEq/hour or 200 mEq per day; oral dosing for hypokalemia: 20-40 mEq 2-4 times daily.

Dosage form	INJECTABLE
Renal impairment	GFR 10-30 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use or use with extreme caution, maximum 40 mEq/day.
Liver impairment	No specific adjustment required; monitor potassium levels closely in severe hepatic impairment due to risk of hyperkalemia.
Pediatric use	0.5-1 mEq/kg/dose intravenously, maximum rate 0.5 mEq/kg/hour; oral: 1-3 mEq/kg/day divided 2-4 times daily.
Geriatric use	Initiate at lower end of dosing range; monitor renal function and potassium levels frequently due to age-related decline in renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE IN PLASTIC CONTAINER (POTASSIUM CHLORIDE IN PLASTIC CONTAINER).

Breastfeeding	Potassium is a normal constituent of breast milk. M/P ratio is approximately 1.0. Supplementation at recommended doses is safe during breastfeeding; excessive doses may cause hyperkalemia in infant, but risk is low at typical therapeutic levels.
Teratogenic Risk	Potassium chloride is considered to have low teratogenic risk. No evidence of fetal harm in first trimester. Normal physiological potassium levels are essential for fetal development; both hypo- and hyperkalemia may pose risks. Second and third trimesters: maternal hyperkalemia can affect fetal cardiac function.

Warnings & precautions

■ FDA Black Box Warning

Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia. High concentrations may cause cardiac arrest. Do not administer undiluted.

Side Effect Profile

Serious Effects

Absolute Contraindications

Severe renal impairment with oliguria, anuria, or azotemia; untreated Addison's disease; adynamia episodica hereditaria; hyperkalemia; conditions causing potassium retention; concurrent use of potassium-sparing diuretics.

Clinical Precautions

Precautions

Risk of hyperkalemia, especially in renal impairment. Monitor serum potassium levels. Use with caution in patients with cardiac disease, adrenal insufficiency, or acid-base disorders. Avoid rapid infusion. Do not add to blood products.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE IN PLASTIC CONTAINER (POTASSIUM CHLORIDE IN PLASTIC CONTAINER).

How it works

Potassium chloride dissociates to potassium ions, which are essential for maintenance of intracellular tonicity, nerve impulse conduction, muscle contraction, and cardiac function.

What the body does with it

Metabolism	Potassium is not metabolized but is primarily excreted by the kidneys. Excreted mainly as potassium ions in urine.
Excretion	Primarily renal (90% excreted unchanged in urine); minor fecal elimination (<10%) via unabsorbed potassium.
Half-life	No classical terminal half-life; plasma potassium is rapidly regulated by cellular uptake and renal excretion, with equilibration half-life of ~1-2 hours in normal renal function.
Protein binding	Not protein-bound (free ion; negligible binding to albumin).
Volume of Distribution	0.5-0.6 L/kg (total body water); distributes primarily in extracellular fluid (14% of body weight).
Bioavailability	Oral: 90-100% (well absorbed from small intestine); IV: 100%.
Onset of Action	IV: Immediate (within seconds to minutes); oral: 30-60 minutes.
Duration of Action	IV: 2-4 hours (rapid redistribution and excretion); oral: 4-6 hours (sustained-release formulations up to 8-12 hours).

Classification & Brands

Dosing & administration

10-20 mEq intravenously over 1 hour, not exceeding 10 mEq/hour or 200 mEq per day; oral dosing for hypokalemia: 20-40 mEq 2-4 times daily.

Dosage form	INJECTABLE
Renal impairment	GFR 10-30 mL/min: reduce dose by 50%; GFR <10 mL/min: avoid use or use with extreme caution, maximum 40 mEq/day.
Liver impairment	No specific adjustment required; monitor potassium levels closely in severe hepatic impairment due to risk of hyperkalemia.
Pediatric use	0.5-1 mEq/kg/dose intravenously, maximum rate 0.5 mEq/kg/hour; oral: 1-3 mEq/kg/day divided 2-4 times daily.
Geriatric use	Initiate at lower end of dosing range; monitor renal function and potassium levels frequently due to age-related decline in renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE IN PLASTIC CONTAINER (POTASSIUM CHLORIDE IN PLASTIC CONTAINER).

Breastfeeding	Potassium is a normal constituent of breast milk. M/P ratio is approximately 1.0. Supplementation at recommended doses is safe during breastfeeding; excessive doses may cause hyperkalemia in infant, but risk is low at typical therapeutic levels.
Teratogenic Risk	Potassium chloride is considered to have low teratogenic risk. No evidence of fetal harm in first trimester. Normal physiological potassium levels are essential for fetal development; both hypo- and hyperkalemia may pose risks. Second and third trimesters: maternal hyperkalemia can affect fetal cardiac function.

Warnings & precautions

■ FDA Black Box Warning

Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia. High concentrations may cause cardiac arrest. Do not administer undiluted.